


Target Price: SAR 161.9/share Upside: 44.8%

Mouwasat Medical Services Co. (N	MOUWASAT)
----------------------------------	-----------

Recommendation	Buy
Current Market Price (SAR)	111.8
52wk High / Low (SAR)	144.0/92.5
Mkt. Cap. (USD/SAR Mn)	5,959/22,360
Shares Outstanding (mn)	200.0
Free Float (%)	65.0%
3m Average Vol. (000)	329
3m Avg Daily Turnover (SAR'000)	42,457
Dividend Yield '24e (%)	1.9%
P/E'24e (x)	30.3
EV/EBITDA'24e (x)	4.1
Source: Bloomberg	

Relative Price Performance



Key Indicators

SAR (mn)	FY2022	FY2023	FY2024e	FY2025e
Revenue	2,334	2,706	2,967	3,235
Gross profit	1,099	1,313	1,420	1,555
Gross margin (%)	47%	49%	48%	48%
EBIT	673	757	835	938
EBIT margin (%)	29%	28%	28%	29%
Net Income	599	658	738	836
Net margin (%)	26%	24%	25%	26%
EPS (SAR)	3.0	3.3	3.7	4.2
RoE (%)	22%	21%	21%	22%

Source: Company Reports, Yaqeen Capital

Major Shareholders (%)

Muhammad Sultan Hammad Al Subaie Nasser Sultan Fahd Al-Arini Al-Subaie Suleiman Muhammad Suleiman Al-Saleem Source: Bloomberg, Yaqeen Capital

Earnings increased annually amid higher revenue

- MOUWASAT's net income surged 3.0% YoY to SAR 172mn in 1Q2024, driven by higher revenue and increased other income. However, quarterly net income decreased by 6.8% due to a revenue decline, with net margins improving to 23.7% (-1.3ppts YoY; -0.1ppts QoQ).
- Revenue rose 8.8% YoY to SAR 606mn in 1Q2024, fueled by increased OPD visits and inpatient occupancy rates, the operation of the Mouwasat Center in Madinah from January 2024, improved contractual terms, better performance of specialized resources, and enhanced operational efficiency. On a quarterly basis, revenue fell by 6.5% due to a seasonal decrease in outpatient visits and occupancy rates, coinciding with Ramadan.
- Gross profit for 1Q2024 was up 5.4% YoY (-12.4% QoQ) to SAR 346mn, while the gross margin decreased by 1.5ppts YoY and 3.3ppts QoQ to 47.8%.
- Operating profit increased 0.6% YoY (-7.2% QoQ) to SAR 195mn in 1Q2024 despite higher general and administrative expenses (+11.0% YoY; +25.4% QoQ), with the operating margins declining by 2.4ppts YoY (+0.5ppts QoQ) to 26.6%.

Outlook & Valuation: Saudi Arabia's healthcare sector is rapidly transforming due to increased life expectancy and rising demand for services. As a leading private healthcare provider, MOUWASAT is well-positioned to capitalize on these changes. The company is quickly expanding its presence by building or acquiring new hospitals across major and remote areas of the kingdom. Revenue is expected to grow steadily, driven by capacity expansion, while market conditions are projected to remain favorable in the coming years. Additionally, MOUWASAT is focused on boosting profitability through operational improvements. Based on relative valuation, we arrive at a fair value of SAR 161.9/share. Considering a healthy upside of 44.8% from the current levels, we recommend a Buy rating on the stock.

Financial Summary

SAR (mn)	1Q2024	1Q2023	YoY	4Q2023	QoQ
Revenue	723	664	9%	773	-7%
Gross profit	346	328	5%	395	-12%
Gross margin (%)	48%	49%		51%	
EBIT	195	194	1%	210	-7%
EBIT margin (%)	27%	29%		27%	
Net Income	172	167	3%	184	-7%
Net margin (%)	24%	25%		24%	
EPS (SAR)	0.9	0.8	3%	0.9	-7%


Source: Company Reports, Yaqeen Capital

17.5%

17.5%

17.5%

Price to Earnings Ratio Trend 60 50 40 30 20 10 0 Aug-23 May-23 Oct-23 Vov-23 Dec-23 Mar-24 Apr-24 un-23 Jul-23 Sep-23 Jan-24 ⁼eb-24 Aay-24



Rating Methodology

Buy: The Target share price exceeds the current share price by $\ge 10\%$

Hold: The Target share price is either more or less than the current share price by 10%

Sell: The Target share price is less than the current share price by $\ge 10\%$

Disclaimer

Research report has been prepared by Yaqeen Capital, Riyadh, Saudi Arabia. It has been prepared for the general use of Yaqeen Capital's clients and may not be altered, redistributed, retransmitted, or disclosed, in whole or in part, or in any form or manner, without the express written consent of Yaqeen Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Yaqeen Capital. The information contained was obtained from various public sources believed to be reliable, and Yaqeen Capital makes no representations or warranties (express or implied) regarding the data and information provided and does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only, but we do not intend to provide personal investment advice and did not constitute an offer or an invitation to make an offer, to buy/ sell/ hold any securities or other investment products. and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report.

Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed in this document and should understand that statements regarding future prospects may not be realized. Investors should note that the securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Yaqeen Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking Group of Yaqeen Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. Yaqeen officers (including research analysts) or Board of directors may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, or other financial instruments. Yaqeen Capital and employees shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this report.

Yaqeen Capital is a closed joint stock company licensed by the Saudi Arabian Capital Market Authority, License No (06020-37) to provide services in Dealing, Custody, Managing, Arranging and Advising.